Similarly to NQO1, NRF2 was elevated in acute lymphoeytic leukemia, cholangiocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, glioblastoma multiforme, glioma, acute myeloid leukemia, brain lower grade glioma, liver hepatocellular carcinoma, pancreatic adenocarcinoma, stomach adenocarcinoma, stomach and esophageal carcinoma; and decreased in kidney chromophobe, kidney renal clear cell carcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, and wilms tumor (Supplementary Figure S2A). This evidence concerns the gene NQO1 and cholangiocarcinoma.